Once-weekly semaglutide lowered body-mass index by 13.5% in children ages 6 to 11 with obesity after 68 weeks, while BMI rose 2.7% on placebo, in the phase 3 STEP Young trial published in the New England Journal of Medicine on November 16, 2026.
No GLP-1 drug is approved in the United States for children younger than 12, trial presenter Martin Wabitsch of Ulm University Medical Center said, according to Healio. Wegovy, the weight-loss brand of semaglutide, has been FDA-approved for ages 12 and older since December 2022, Healio and Fierce Pharma report. STEP Young is now the main evidence pediatricians, residents and students will weigh when families ask whether a child this young should take an obesity drug.
By week 68, 38% of children on semaglutide had a BMI below the obesity threshold, compared with 2% on placebo.
The numbers: 167 children, two years, a 16-point gap
The trial randomly assigned 167 children 2:1 to weekly semaglutide (112) or placebo (55) for 104 weeks, followed by a 7-week washout, and both groups received lifestyle counseling, according to the NEJM abstract indexed in PubMed. The maximum dose was 1.7 mg or 2.4 mg depending on baseline weight, and more than 85% of the children had class II or III obesity, Novo Nordisk said.
- Week 68 (primary end point): BMI fell 13.5% with semaglutide and rose 2.7% with placebo, a difference of 16.2 percentage points.
- BMI category: 79% of children on semaglutide moved down at least one BMI category, compared with 23% on placebo.
- Week 104: BMI was 9.4% lower with semaglutide and 8.4% higher with placebo, a 17.8-point gap.
- Safety: adverse events occurred in 96% of children on semaglutide and 93% on placebo, mostly gastrointestinal. GI events led one child on semaglutide to stop treatment. Vomiting affected 70% versus 29%, Healio reported from the meeting presentation.
The results were also presented at ObesityWeek, held November 14-17 in National Harbor, Maryland, according to Healio. Novo Nordisk, which makes semaglutide, funded the trial.
Check the estimand before you quote a number
Different headlines carry different numbers for the same trial. In September, Novo Nordisk's topline announcement said 40.4% of treated children were no longer classified as having obesity, a figure its own footnote says assumes every child stayed on treatment.
The journal's 13.5% comes from the more conservative treatment-regimen analysis. Contemporary Pediatrics noted that the company's 17.4% BMI figure comes from the efficacy estimand. On rounds or in journal club, ask which analysis a number comes from: the treatment-regimen result is closer to what happens in clinic, where children miss doses or stop because of nausea.
A second habit for pediatrics: judge children by BMI and percentiles, not the scale. BMI rose 8.4% in the placebo group over two years. In the earlier liraglutide trial in the same age group, body weight rose in both arms even as BMI fell with the drug.
More than double the liraglutide effect, with caveats
The closest comparison is SCALE Kids, Novo Nordisk's phase 3 trial of daily liraglutide in children 6 to under 12, published in NEJM in September 2024. BMI fell 5.8% with liraglutide and rose 1.6% with placebo after 56 weeks, a 7.4-point gap.
STEP Young's 16.2-point gap is more than twice that. The trials differ in drug, dose, length and size, so this is a cross-trial comparison, not a head-to-head result.
What we don't know yet
- What happens after stopping. Lead author Ania Jastreboff of Yale said BMI rose in the semaglutide group during the washout, and 26 weeks of off-drug data are expected in the coming months, Healio reported.
- Whether the effect holds. The BMI reduction narrowed between weeks 68 and 104, and longer data on growth, puberty and durability are still needed, Contemporary Pediatrics noted.
- Growth and puberty so far. Antje Körner of the University of Leipzig reported no effects on puberty progression or bone mineral density, according to Healio.
- Who should get it. The American Academy of Pediatrics' 2023 guideline addresses obesity drugs for adolescents 12 and older. In a commentary, Daniel Hsia of Emory University said the results support "a paradigm shift moving away from watchful waiting," but that many questions remain about younger children. Hsia disclosed advising Eli Lilly and research work for Lilly and Novo Nordisk.
- Regulatory plans. Novo Nordisk's announcement does not mention a filing for this age group.
What to do now
- Students: know the definitions the trial used. Obesity in children is a BMI at or above the 95th percentile for age and sex; class II is at least 120% and class III at least 140% of that cutoff. Drill pediatrics in MedRise Board Review.
- Know the trade-off: vomiting, diarrhea and nausea were each reported in more than half of children on semaglutide, Healio reported, so counseling on GI effects is part of any GLP-1 discussion.
- Residents: when families ask, the accurate answer today is that semaglutide is not FDA-approved under 12, and the trial data are two years long and sponsor-funded. Decisions belong to the treating clinician and family. More for trainees on MedRise for residents and MedRise for students.
STEP Young moves the question from whether semaglutide works in young children to what happens when they stop. The off-drug data due next may matter as much as the 13.5%.
Sources
- Jastreboff AM, et al. Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age. N Engl J Med, Nov. 16, 2026 (doi:10.1056/NEJMoa2604058)
- PubMed record 43037562
- Fox CK, et al. Liraglutide for Children 6 to <12 Years of Age with Obesity. N Engl J Med, 2024 (doi:10.1056/NEJMoa2407379)
- Novo Nordisk, STEP Young topline results
- Healio, ObesityWeek report, Nov. 16, 2026
- Contemporary Pediatrics, Nov. 16, 2026
- Fierce Pharma, Sept. 8, 2026
MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.



